Medicine Classification Schedules




19 APRIL 2007

NEW ZEALAND GAZETTE, No. 43

Schedule 1

Prescription Medicines
Abatacept
Aliskiren
Amyl nitrite; except when sold from outlets licensed to sell cyanide paste for the purpose of vertebrate pest control
Azelastine; except when specified elsewhere in the Schedule
Chlorquinaldol
Choline salicylate; except in medicines containing 10% or less and in pack sizes of 15 grams or less
Darunavir
Dasatinib
Deslorelin
Dimethoxinate
Diphenylpyraline
Etidronic acid; except in medicines for external use containing 1% or less
Fomivirsen
Fosaprepitant
Ipriflavone
Lanthanum
Lapatinib
Lefetamine
Levonorgestrel; except when specified elsewhere in the Schedule; except in medicines for use as emergency post-coital contraception when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health
Lithium; except when specified elsewhere in the Schedule; except when present as an excipient in dermal medicines containing 0.25% or less
Lodoxamide; except in medicines for ophthalmic use
Natalizumab
Nepafenac
Nilotinib
Olmesartan
Oxiconazole; except when specified elsewhere in the Schedule
Palifermin
Paliperidone
Pegvisomant
Pyridoxal; in medicines containing more than 200 milligrams per recommended daily dose
Pyridoxamine; in medicines containing more than 200 milligrams per recommended daily dose
Rasagilin
Riluzole
Rimexolone
Rimonabant
Ruboxistaurin
Sabadilla
Schoenocoulon officinale
Scopolia carniolica
Tipepidine
Tolpropamine
Vildagliptin

Schedule 2

Restricted Medicines
Azelastine; in medicines for ophthalmic use containing 0.05% or less
Levonorgestrel; in medicines for use as emergency post-coital contraception when in packs containing

not more than 1.5 milligrams except when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health
Oxiconazole; for vaginal use
Salicylic acid; except in medicines for dermal use containing 40% or less

Schedule 3

Pharmacy-only Medicines
Beclomethasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine

Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine

Diclofenac; in solid dose form in medicines containing 12.5 milligrams or less per dose form in packs containing not more than 20 tablets or capsules and with a recommended daily dose of not more than 75 milligrams

Fluticasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation and when the maximum recommended daily dose is no greater than 200 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine

Ibuprofen; for oral use in liquid form in packs containing not more than 4 grams in medicines which have received the consent of the Minister or the Director-General to their sale as pharmacy-only medicines and which are sold in the manufacturer’s original pack; for oral use in solid dose form containing not more than 200 milligrams per dose form and with a recommended daily dose of not more than 1200 milligrams and in packs containing not more than 100 tablets or capsules and when in medicines which have received the consent of the Minister or the Director-General to their sale as pharmacy-only medicines and which are sold in the manufacturer’s original pack; except in packs containing 200 milligrams or less per oral solid dose form and not more than 25 dose units per pack when in medicines which have received the consent of the Minister or the Director-General to their sale as general sale medicines and which are sold in the manufacturer’s original pack

Lithium; for dermal use in medicines containing 1% or less but more than 0.01%; except when present as an excipient in dermal medicines containing 0.25% or less

Lobeline; except when in medicines for smoking or burning

Mometasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation and when the maximum recommended daily dose is no greater than 200 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine

Oxiconazole; for dermal use except in medicines for tinea pedis only

1155



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2007, No 43


Gazette.govt.nz PDF NZ Gazette 2007, No 43





✨ LLM interpretation of page content

🏥 Classification of Medicines (continued from previous page)

🏥 Health & Social Welfare
Medicines, Classification, Prescription, Restricted, Pharmacy-only